Two clinical trials for Bristol-Myers Squibb's Vanlev have failed to prove the drug's efficacy on patients suffering from heart failures. Analysts had predicted the drug would generate $3 billion in sales for the company, which designed the drug to treat congestive heart failure and high blood pressure. Researchers say Vanlev failed to establish a clear benefit over Merck's Vasotec.

Related Summaries